Welcome to our dedicated page for Aytu Biopharma SEC filings (Ticker: AYTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Most Aytu BioPharma investors start with two questions: How quickly is the pediatric ADHD franchise scaling, and what are insiders doing with their shares? Those answers live inside a maze of 10-Ks, 10-Qs, 8-Ks and Form 4s. Our SEC filings hub guides that journey from first click to final model.
Type a natural query—“Aytu BioPharma quarterly earnings report 10-Q filing” or “Aytu BioPharma insider trading Form 4 transactions”—and land on real-time disclosures the moment they hit EDGAR. Stock Titan’s AI instantly produces concise, plain-English summaries, turning dense sections on R&D spend or revenue by therapeutic class into actionable paragraphs. You’ll also find:
- Aytu BioPharma annual report 10-K simplified—cash runway, ADHD sales mix, urology pipeline timelines
- Aytu BioPharma Form 4 insider transactions real-time—executive stock transactions and option exercises
- Aytu BioPharma 8-K material events explained—from trial data releases to licensing agreements
- Aytu BioPharma proxy statement executive compensation—equity incentives and board alignment
Need deeper context? Select “understanding Aytu BioPharma SEC documents with AI” to compare footnote language across quarters or generate ratio tables without touching a spreadsheet. Practical use cases include monitoring Form 4 insider buys ahead of FDA milestones, reviewing segment revenue trends for earnings-report filing analysis, and flagging covenant changes hidden in debt footnotes.
Whether you’re screening small-cap pharma, preparing a due-diligence memo, or tracking Aytu BioPharma executive stock transactions Form 4, our platform surfaces what matters and updates the moment the company files. Complex SEC filings explained simply—so you can act before the market does.
Amendment No. 2 to Schedule 13G discloses that several related entities – Philotimo Fund LP, Philotimo Focused Growth & Income Fund (a series of World Funds Trust), Kanen Wealth Management LLC, and David L. Kanen – collectively own 166,268 shares of AYTU BioPharma, Inc. common stock.
Based on the issuer’s 6,170,246 shares outstanding as of 1 May 2025, the group’s holding represents approximately 2.7 % of the company’s equity.
Individually, Philotimo Fund holds 111,400 shares (1.8 %), while the Philotimo Focused Growth & Income Fund holds 54,868 shares (0.9 %). Kanen Wealth Management, as general partner and investment manager, and Mr. Kanen, as managing member, are each deemed to beneficially own all 166,268 shares through shared voting and dispositive power. No party reports sole voting or dispositive authority; all authority is shared among the reporting persons.
The filing is made pursuant to Rule 13d-1(c), indicating a passive investment below the 5 % threshold that would require a Schedule 13D. Each reporting person expressly disclaims beneficial ownership of shares not directly held. The event triggering the filing occurred on 22 May 2025, and the ownership percentages rely on share-count data from AYTU’s 14 May 2025 Form 10-Q.
Because the combined stake is below 5 %, the amendment does not signal a change in control or confer significant influence; however, it formally records the aggregated position and clarifies governance relationships among the entities.
FAQ
What is the current stock price of Aytu Biopharma (AYTU)?
What is the market cap of Aytu Biopharma (AYTU)?
What is the primary focus of Aytu BioPharma Inc?
Which therapeutic areas does Aytu BioPharma address?
What significant strategic changes has the company implemented recently?
How does Aytu BioPharma generate its revenue?
What distinguishes Aytu BioPharma from other specialty pharmaceutical companies?
How does the company ensure the quality and innovation of its products?
Who are the target patients for the company’s products?
